Psychemedics (PMD) 10-Q 2004 Q1 Quarterly report

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

(X) QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For quarterly period endedMarch 31, 2004

(   ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from               to               

Commission file number 1-13738

PSYCHEMEDICS CORPORATION

(exact name of Issuer as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation of organization) 58-1701987
(I.R.S. Employer
Identification No.)

1280 Massachusetts Ave., Suite 200, Cambridge, MA
(Address of principal executive offices) 02138
(Zip Code)

Issuer’s telephone number, including area code (617) 868-7455

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes (X) No (   )

Indicate by check mark whether the registrant is an accelerated filer.

YES ( ) NO (X)

Number of shares outstanding of only class of Issuer’s Common Stock as of May 12, 2004: Common Stock $.005 par value (5,126,907 shares).

PSYCHEMEDICS CORPORATION

		Page No.
Part I FINANCIAL INFORMATION
Item 1	Financial Statements (Unaudited)
	Condensed Balance Sheets as of March 31, 2004 and December 31, 2003		3
	Condensed Statements of Income for the three month periods ended March 31, 2004 and 2003		4
	Condensed Statements of Cash Flows for the three month periods ended March 31, 2004 and 2003		5
	Notes to Condensed Financial Statements		6-8
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations		9-13
Item 3	Quantitative and Qualitative Disclosures about Market Risk		13
Item 4	Controls and Procedures		14
Part II OTHER INFORMATION
Item 6	Exhibits and Reports on Form 8-K		14
SIGNATURES			15
EXHIBIT INDEX			17
Ex-31.1 Certification of CEO
Ex-31.2 Certification of CFO
Ex-32.1 Certification of CEO pursuant to Sec 906
Ex-32.2 Certification of CFO pursuant to Sec 906

2

PSYCHEMEDICS CORPORATION

CONDENSED BALANCE SHEETS

	MARCH 31,			DECEMBER 31,
	2004			2003
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	2,547,828		$	3,022,467
Accounts receivable, net		2,698,655			2,149,942
Prepaid expenses and other assets		576,142			324,974
Deferred tax asset		445,012			445,012
Total current assets		6,267,637			5,942,395
PROPERTY AND EQUIPMENT:
Equipment and leasehold improvements, at cost		9,597,922			9,583,553
Less-accumulated depreciation and amortization		(8,755,869	)		(8,633,238	)
		842,053			950,315
DEFERRED TAX ASSET		240,691			240,691
OTHER ASSETS, NET		116,751			133,590
	$	7,467,132		$	7,266,991
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	627,071		$	398,171
Accrued expenses		1,237,424			1,325,540
Deferred revenue		448,926			432,404
Total current liabilities		2,313,421			2,156,115
SHAREHOLDERS’ EQUITY:
Preferred stock, $0.005 par value; 872,521 shares authorized; none issued or outstanding		—			—
Common stock; $0.005 par value; 50,000,000 shares authorized; 5,710,704 shares in 2003 and 2002 issued		28,554			28,554
Paid-in capital		24,978,039			24,978,039
Accumulated deficit		(10,730,191	)		(10,773,026	)
Less — Treasury stock, at cost; 583,797 shares		(9,122,691	)		(9,122,691	)
Total shareholders’ equity		5,153,711			5,110,876
	$	7,467,132		$	7,266,991

See accompanying notes to financial statements and management’s discussion and
analysis of financial condition and results of operations.

3

PSYCHEMEDICS CORPORATION

CONDENSED STATEMENTS OF INCOME

(UNAUDITED)

	THREE MONTHS
	ENDED MARCH 31,
	2004		2003
REVENUE	$	4,155,872	$	3,657,567
DIRECT COSTS		2,004,706		1,925,314
Gross profit		2,151,166		1,732,253
EXPENSES:
General and administrative		743,801		767,312
Marketing and selling		606,529		713,043
Research and development		77,019		83,734
		1,427,349		1,564,089
OPERATING INCOME		723,817		168,164
INTEREST INCOME		7,921		11,175
OTHER INCOME		3,750		—
		11,671		11,175
NET INCOME BEFORE INCOME TAXES		735,488		179,339
PROVISION FOR INCOME TAXES		282,500		75,000
NET INCOME	$	452,988	$	104,339
BASIC NET INCOME PER SHARE	$	0.09	$	0.02
DILUTED NET INCOME PER SHARE	$	0.09	$	0.02
DIVIDENDS DECLARED PER SHARE	$	0.08	$	0.08
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING		5,126,907		5,214,325
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING, ASSUMING DILUTION		5,133,050		5,222,190

See accompanying notes to financial statements and management’s discussion and
analysis of financial condition and results of operations.

4

PSYCHEMEDICS CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	THREE MONTHS
	ENDED MARCH 31,
	2004			2003
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	452,988		$	104,339
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization		139,470			240,978
Changes in current assets and liabilities:
Accounts receivable		(548,713	)		(251,584	)
Prepaid expenses and other assets		(251,168	)		(299,873	)
Accounts payable		228,900			249,512
Accrued expenses		(88,116	)		(51,214	)
Deferred revenue		16,522			14,862
Net cash provided by (used in) operating activities		(50,117	)		7,020
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(14,369	)		(50,756	)
Net cash used in investing activities		(14,639	)		(50,756	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash dividends paid		(410,153	)		(417,098	)
Acquisition of treasury stock		—			(24,318	)
Net cash used in financing activities		(410,153	)		(441,416	)
NET DECREASE IN CASH AND CASH EQUIVALENTS		(474,639	)		(485,152	)
CASH AND CASH EQUIVALENTS, beginning of period		3,022,467			3,648,913
CASH AND CASH EQUIVALENTS, end of period	$	2,547,828		$	3,163,761

See accompanying notes to financial statements and management’s discussion and
analysis of financial condition and results of operations.

5

PSYCHEMEDICS CORPORATION

NOTES TO FINANCIAL STATEMENTS

March 31, 2004

1. Interim Financial Statements

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the financial statements and related notes of Psychemedics Corporation (the “Company”) as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2003. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of financial position, results of operations, and cash flows at the dates and for the periods presented have been included. The results of operations for the three months ended March 31, 2004 may not be indicative of the results that may be expected for the year ending December 31, 2004, or any other period.

2. Stock-Based Compensation

The Company accounts for its stock compensation arrangements with employees under the provisions of Accounting Principles Board (APB) Opinion No. 25,Accounting for Stock Issued to Employees. The Company has adopted the disclosure-only provisions of SFAS No. 123,Accounting for Stock-Based Compensation.

Statement of Financial Accounting Standards, (SFAS) No. 123,Accounting for Stock-Based Compensation, requires the measurement of the fair value of stock options or warrants to be included in the statement of income or disclosed in the notes to financial statements. The Company has computed the value of options using the Black-Scholes option pricing model prescribed by SFAS No. 123.

The assumptions used and the weighted average information are as follows:

	Three Months Ended
	March 31,			March 31,
	2004			2003
Risk-free interest rates		2.70	%		2.82	%
Expected dividend yield		2.7	%		3.5	%
Expected lives	5 years			5 years
Expected volatility		27.94	%		36.35	%

6

Consistent with SFAS No. 123, net income (loss) and basic and diluted net income (loss) per share would have been as follows:

	Three Months Ended
	March 31,			March 31,
	2004			2003
Net income, as reported	$	452,988		$	104,339
Add: Stock based employee compensation cost, included in the determination of net income as reported		—			—
Less: Total stock based compensation cost determined under the fair value based method for all employee awards		(25,671	)		(50,369	)
Pro forma net income	$	427,317		$	53,970
Net income per share:
Basic and diluted, as reported	$	0.09		$	0.02
Basic and diluted, pro forma	$	0.08		$	0.01

The fair value of options granted for the three months ended March 31, 2004 and 2003 was $2.86 per share and $2.85 per share, respectively.

3. Basic and Diluted Net Income Per Share

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share was computed by dividing net income by the weighted average number of common and dilutive common equivalent shares outstanding during the period. The number of dilutive common equivalent shares outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options.

     Basic and diluted weighted average common shares outstanding are as follows:

	Three Months Ended
	March 31,		March 31,
	2004		2003
Weighted average common shares outstanding		5,126,907		5,214,325
Dilutive common equivalent shares		6,143		7,865
Weighted average common shares outstanding, assuming dilution		5,133,050		5,222,190

For the three months ended March 31, 2004 and 2003, options to purchase 362,925 and 455,805 common shares, respectively, were outstanding but not included in the

7

diluted weighted average common share calculation as the effect would have been antidilutive.

4. Revenue Recognition

The Company performs drug testing as well as provides training for collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit tested of samples. The revenues are recognized when the predominant deliverable, drug testing, is provided and reported to the customer. The Company also provides expert testimony, when and if necessary, to support the results of the tests, which is generally billed separately and recognized as the services are provided.

In 2003, the Company adopted Emerging Issue Task Force 00-21,Revenue Arrangements with Multiple Deliverables, which was effective for all transactions entered into subsequent to June 15, 2003. The Company applied the consensus reached under EITF 00-21 and concluded that the testing, training and storage elements are considered one unit of accounting for revenue recognition purposes as the training and storage costs do not have stand-alone value to the customer. The Company has concluded that the predominant deliverable in the arrangement is the testing of the units and has recognized revenue as that service is performed and reported to the customer.

At March 31, 2004 and December 31, 2003, the Company had deferred revenue of approximately $449,000 and $432,000, respectively, reflecting sales of its personal drug testing service for which the performance of the related test had not yet occurred.

5. Reclassifications

The Company has reclassified the cost of collecting hair samples from sales and marketing expenses to cost of services to permit comparison with the current year. The impact of this reclassification reduced gross profit by $158,819 in the first quarter of 2003 and was offset by reduced sales and marketing expenses of $158,819 in the first quarter of 2003, but had no effect on operating income or net income in the first quarter of 2003.

6. Recent Accounting Pronouncements

In January 2003, the FASB issued Interpretation No. 46, Consolidation of Variable Interest Entities. In December 2003, the FASB issued a revised interpretation. Interpretation No. 46 requires variable interest entities to be consolidated if the total equity investment at risk is not sufficient to permit the entity to finance its activities without financial support from other parties or the equity investors lack certain specified characteristics of a controlling financial interest. The guidelines of Interpretation No. 46 were applicable for the Company during the first quarter of 2004. The Company adoption of Interpretation No. 46 did not have any impact on the Company’s consolidated financial statements.

8

Item 2

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

Psychemedics Corporation was incorporated in 1986. The Company utilizes a patented hair analysis method involving radioimmunoassay technology to analyze human hair to detect abused substances.

Revenue was $4.2 million for the first quarter of 2004 and was 14% above revenue of $3.7 million for the first quarter of 2003. Due to the increase in revenue and by maintaining tight controls over expenses, the Company reported net income of $0.09 in the quarter ended March 31, 2004 and $0.02 per share in the quarter ended March 31, 2003. At March 31, 2004, the Company had $2.5 million of cash and cash equivalents. During the first quarter of 2004, the Company distributed $0.4 million, or $0.08 per share, of cash dividends to its shareholders. As of the date of this Report, the Company has paid thirty consecutive quarterly cash dividends.

RESULTS OF OPERATIONS

Revenue was $4,155,872 for the three month period ended March 31, 2004 as compared to $3,657,567 for the comparable period of 2003, representing an increase of 14%. The increase in revenue for the first quarter of 2004 was due to an increase of 13% in testing volume from both new and existing clients, while the average revenue per sample increased by 1% as compared to the comparable period of 2003. The Company continued to add approximately the same number of new clients in the first quarter of 2004 as it did in the first quarter of 2003.

Gross margin was 52% of revenue for the three month period ended March 31, 2004, as compared to 47% for the comparable period of 2003. Reduced depreciation and amortization expense contributed to a decline in fixed costs for the three month period ended March 31, 2004 as compared to the year earlier period. Also, fixed and semi-variable direct costs were spread over a greater number of tests performed and average revenue per sample increased by 1% for the three month period ended March 31, 2004, as compared to the same period of 2003.

General and administrative (“G&A”) expenses were $743,801 for the three month period ended March 31, 2004 as compared to $767,312 for the comparable period of 2003, representing a decrease of 3%. The decrease in general and administrative expenses was due primarily to reduced personnel expenses and a reduction in bad debt expense, partially offset by greater professional fees related to investor relations, legal services and accounting services and an increase in business insurance costs. All other general and administrative expenses remained relatively constant. As a percentage of revenue, G&A expenses represented 18% of revenues in the first quarter of 2004 and 21% of revenues in the first quarter of 2003.

Marketing and selling expenses were $606,529 for the three month period ended March 31, 2004 as compared to $713,043 for the comparable period of 2003, a decrease of 15%. This decrease was due primarily to a reduction in personnel expenses pertaining to the Company’s sales and support staff for the three months ended March 31, 2004 as compared to the comparable period of 2003. Total marketing and selling expenses

9

represented 15% of revenues in the first quarter of 2004 and 19% of revenues in the first quarter of 2003 due to reduced selling costs. Additionally, revenues growth also reflected the results of higher previous selling efforts, which often include longer lead times. The Company expects to continue to aggressively promote its drug testing services during the remainder of 2004 and in future years in order to expand its client base.

Research and development (“R&D”) expenses were $77,019 for the three month period ended March 31, 2004 as compared to $83,734 for the comparable period of 2003, a decrease of 8%. This decrease was primarily due to reduced personnel and consumables costs. R&D expenses represented 2% of revenues for the three month periods ended March 31, 2004 and 2003.

Interest income for the three month period ended March 31, 2004 decreased by $3,254 as compared to the year earlier period and represented interest earned on cash equivalents. Lower average investment balances along with a decrease in the yield on investment balances in the first quarter of 2004 as compared to the first quarter of 2003 caused the decrease in interest income.

During the three months ended March 31, 2004, the Company recorded a tax provision of $282,500 reflecting an effective tax rate of 38.4% as compared to a tax provision of $75,000 and an effective tax rate of 41.8% for the three months ended March 31, 2003. The lower effective tax rate for the quarter ended March 31, 2004 as compared to the quarter ended March 31, 2003 was due primarily to reduced state income taxes due to lower expected state taxes than provided for in the prior year.

LIQUIDITY AND CAPITAL RESOURCES

At March 31, 2004, the Company had approximately $2.5 million of cash and cash equivalents. The Company’s operating activities used net cash of $50,117 in the three months ended March 31, 2004. Investing activities used $14,369 in the three month period while financing activities used a net amount of $410,153 during the period.

Cash used by operating activities of $50,117 principally reflected net income of $452,988 adjusted for depreciation and amortization of $139,470 offset primarily by the growth in accounts receivable and prepaid expenses.

Capital expenditures in the first three months of 2004 were $14,369. The expenditures primarily consisted of new equipment, including laboratory and computer equipment. The Company currently plans to make capital expenditures of approximately $700,000 in 2004, primarily in connection with the purchase of additional laboratory and computer equipment. The Company believes that within the next two to four years it may be required to expand its existing laboratory or develop a second laboratory, the cost of which is currently believed to range from $2 million to $4 million, which the Company expects to fund primarily through its operating cash flows.

During the three month period ended March 31, 2004, the Company distributed $410,153 in cash dividends to its shareholders. The Company did not repurchase any shares for treasury during the quarter ended March 31, 2004. The Company has authorized 500,000 shares for repurchase since June of 1998 of which 466,351 shares have been repurchased.

10

Contractual obligations as of March 31, 2004 were as follows:

	Less Than		1-3		4-5		After 5
	One Year		Years		years		Years		Total
Operating leases	$	487,000		356,000		—		—	$	843,000

     Purchase Commitment

The Company has a supply agreement with a vendor which requires the Company to purchase isotopes used in its drug testing procedures from this sole supplier in exchange for variable annual payments based upon prior year purchases. Purchases amounted to $109,719 for the three months ended March 31, 2004 as compared to $109,401 for the comparable period of 2003. The Company expects to purchase approximately $439,000 for all of 2004. In exchange for exclusivity, the supplier has provided the Company with the right to purchase the isotope technology at fair market value under certain conditions, including the failure to meet the Company’s purchase commitments. This agreement does not include a fixed termination date, however, it is cancelable upon mutual agreement by both parties or six months after termination notice by the Company of its intent to use a different technology in connection with its drug testing procedures.

At March 31, 2004, the Company’s principal sources of liquidity included an aggregate of approximately $2.5 million of cash and cash equivalents. Management currently believes that such funds, together with cash generated from operations, should be adequate to fund anticipated working capital requirements and capital expenditures in the near term. Depending upon the Company’s results of operations, its future capital needs and available marketing opportunities, the Company may use various financing sources to raise additional funds. Such sources could potentially include joint ventures, issuances of common stock or debt financing, although the Company does not have any such plans at this time. At March 31, 2004, the Company had no long-term debt.

CRITICAL ACCOUNTING POLICIES

Management believes the most critical accounting policies are as follows:

     Revenue Recognition

The Company is in the business of performing drug testing and reporting the results thereof. The Company performs drug testing which includes training for collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit tested of samples. The revenues are recognized when the predominant deliverable, drug testing, is provided and reported to the customer. The Company also provides expert testimony, when and if necessary, to support the test results, which is generally billed separately and recognized as the services are provided.

In 2003, the Company adopted Emerging Issue Task Force 00-21,Revenue Arrangements with Multiple Deliverables, which was effective for all transactions entered into subsequent to June 15, 2003. The Company applied the consensus reached under EITF 00-21 and concluded that the testing, training and storage elements are considered one unit of accounting for revenue recognition purposes as the training and storage costs do not have stand-alone value to the customer. The Company has concluded that the predominant deliverable in the arrangement is the

11

testing of the units and has recognized revenue as that service is performed and reported to the customer.

Deferred revenue represents payments received in advance of the performance of drug testing procedures. Deferred revenue is reclassified as revenue when the underlying test results are delivered. With respect to a portion of these transactions, there may be instances where the customer ultimately does not require performance (referred to as breakage). Revenue is then recognized (as other income) when the Company can reasonably, reliably and objectively determine the breakage has occurred. Breakage is deemed to occur only at the point it becomes remote that performance will be required. The Company has not recorded any breakage in the first quarter of 2004 and during 2003. The Company continues to monitor this to determine whether breakage can be reasonably, reliably and objectively determined.

     Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates, including bad debts and income taxes, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

     Allowance for Doubtful Accounts

The allowance for doubtful accounts is based on management’s assessment of the collectibility of its customer accounts. Management reviews its accounts receivable aging for doubtful accounts and specifically identifies accounts that may not be collectible. The Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. Bad debt expense and the issuance of credit memos have been within management’s expectations.

     Income Taxes

The Company accounts for income taxes using the liability method, which requires the Company to recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences between the financial statement and tax reporting bases of assets and liabilities to the extent that they are realizable. Deferred tax expense (benefit) results from the net change in deferred tax assets and liabilities during the year. A deferred tax valuation allowance is required if it is more likely than not that all or a portion of the recorded deferred tax assets will not be realized.

The Company operates within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits may involve complex issues, which may require an extended period of time to resolve. The Company has provided for its estimated taxes payable in the accompanying financial statements.

12

     Stock-Based Compensation

The Company accounts for its stock compensation arrangements with employees under the provisions of Accounting Principles Board (APB) Opinion No. 25,Accounting for Stock Issued to Employees. The Company has adopted the disclosure-only provisions of SFAS No. 123,Accounting for Stock-Based Compensation, as amended by SFAS No. 148,Accounting for Stock-Based Compensation – Transition and Disclosure.

The above listing is not intended to be a comprehensive list of all of the Company’s accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by accounting principles generally accepted in the United States, with no need for management’s judgment in their application. There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result.

FACTORS THAT MAY AFFECT FUTURE RESULTS

From time to time, information provided by the Company or statements made by its employees may contain “forward-looking” information which involves risks and uncertainties. In particular, statements contained in this report which are not historical facts (including, but not limited to, the Company’s expectations regarding revenues, business strategy, anticipated operating results, strategies with respect to governmental agencies and regulations, cash dividends, capital expenditures and anticipated cash requirements) may be “forward-looking” statements. The Company’s actual results may differ from those stated in any “forward-looking” statements. Factors that may cause such differences include, but are not limited to, employee hiring practices of the Company’s principal customers, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with possible expansion of testing facilities used by the Company, government regulation (including, but not limited to, Food and Drug Administration regulations), competition and general economic conditions. With respect to the continued payment of cash dividends, factors include, but are not limited to, available surplus, cash flow, capital expenditure reserves required, and other factors that the Board of Directors of the Company may take into account.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The Company’s exposure to market risk related to changes in interest rates is limited as the Company maintains a short-term investment portfolio consisting principally of money market securities that are not sensitive to sudden interest rate changes. The Company does not use derivative financial instruments for speculative or trading purposes.

Interest Rate Sensitivity. The Company maintains a short-term investment portfolio consisting principally of money market securities that are not sensitive to sudden interest rate changes.

Item 4. Controls and Procedures

As of the date of this report, our Chief Executive Officer and Chief Financial Officer performed an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rule 13a-14.

13

Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures are effective in ensuring the reporting of material information required to be included in the Company’s periodic filings with the Securities and Exchange Commission. There were no significant changes in the Company’s internal controls over financial reporting or in other factors that could significantly affect these internal controls over financial reporting subsequent to the date of the most recent evaluation.

PART II OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

(a)	Exhibits
	See Exhibit Index included in this Report
	No reports on Form 8-K were filed during the quarter for which this report is filed.

14

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Psychemedics Corporation
Date: May 12, 2004	By:	/s/ Raymond C. Kubacki, Jr.
	Raymond C. Kubacki, Jr.
	Chairman and Chief Executive Officer
Date May 12, 2004	By:	/s/ Peter C. Monson
	Peter C. Monson
	Vice President, Treasurer &
	Chief Financial Officer

15

PSYCHEMEDICS CORPORATION
FORM 10-Q
March 31, 2004

EXHIBIT INDEX

		Page No.
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002		17
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002		19
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002		21
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002		22

16